Momentive Performance Materials collaborates with SSF to develop combination products

Momentive Performance Materials Inc. today announced a collaboration initiative with Specialty Silicone Fabricators (SSF) to develop combination products for medical devices manufacturers. Focusing on the fast-growing market of combination devices with Active Pharmaceutical Ingredients (APIs), the collaboration brings together Momentive Performance Materials advanced silicone elastomer technology with SSF expertise in silicone extrusion and medical device assembly.

“We see the market for combination devices as a major opportunity for innovation”

The collaboration leverages Momentive Performance Materials' advanced ultraviolet (UV) elastomer cure technology, which typically offers fast cure of specialized silicone products at room temperature. Specialty silicone products featuring the UV cure technology, such as Addisil* UV 60 EX elastomer, are excellent candidates to consider in the manufacture of medical devices where lower temperatures are required for heat-sensitive APIs and other materials. The new technology can provide a number of other benefits as well, including production output with high purity and low levels of extractables.

"Silicone is an ideal matrix material to consider for a wide range of healthcare applications, and our UV cure technology will enable manufacturers to consider a much broader range of ingredients in their silicone mixtures," said Lynn Colucci-Mizenko, Global Marketing Director at Momentive Performance Materials. "We have conducted successful trials with SSF to optimize the UV curing extrusion process, and the results have confirmed our high expectations."

The combined focus also takes advantage of SSF's experience and capabilities in the manufacture of custom silicone components and parts for the medical devices industry, including a Class 10,000 clean room for handling pharmaceutical components. Licensed to operate as a drug manufacturing facility and registered with the FDA's Center for Drug Evaluation and Research, SSF is planning to expand its API/drug eluting device production into another clean room that will house its own extrusion line and a larger press to meet growing customer demand.

"We see the market for combination devices as a major opportunity for innovation," said Mark Paulsen, Director, Business Development, at Specialty Silicone Fabricators. "By combining our specialized resources and expertise in medical devices with Momentive Performance Materials' platform technology, we are well positioned to help customers explore their most promising possibilities in combination drug products."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease